DCTH - Delcath Systems Inc
NYSE * Health Care * Health Care Equipment & Supplies
$10.19
$-0.18 (-1.74%)
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
DCTH Key Statistics
Market Cap
$359.85M
P/E Ratio
339.67
P/B Ratio
3.08
EPS
$0.03
Revenue Growth
+0.8%
Profit Margin
0.0%
Employees
76
How DCTH Compares to Peers
P/E Rank
#6
of 6
Margin Rank
#6
of 6
Growth Rank
#4
of 6
Size Rank
#6
of 6
Delcath Systems Inc Company Information
- Headquarters
- New York; U.S.A
- Website
- www.delcath.com
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies